# Symbio Generrics India Private

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symbio-generrics-india-private

- Industry: Pharmaceuticals
- Headquarters: Bangalore, India
- Website: www.symbiogenerics.com
- Total disclosed funding: $13M
- Latest round: Series B (Mar 3, 2022)
- Investors on record: 1

## About

Based in Karnataka, India, and founded in 2010, Symbio Generrics India Private Limited operates as a manufacturer of pharmaceutical products. In November 2022, the firm raised an investment from investor Ascent Capital. The firm as of February 2023,has  2 offices in Mumbai and Bangalore, 1 research and development facility in Bangalore, and 2 manufacturing facilities including VPL Chemicals Pvt Ltd, a fully owned subsidiary, in Vizag and Bengaluru, and is led by its founder and Chairman, Salim Shaikh and Managing Director and CEO, Akash Puranik.

The company manufactures and markets intermediates and active pharmaceutical ingredients (APIs) in IP (Indian Pharmacopoeia), BP (British Pharmacopoeia) and USP (United State Pharmacopoeia) standards for emerging and regulated markets. The company with reaction and processing capabilities including hydrogenation, high-temperature reactions, gas purging etc. also offers contract development and manufacturing (CDMO) services.

The company plans to utilize its November 2022 funding for further acquisitions and improvement of research and development and manpower facilities.

## Funding rounds

- Series B, Mar 3, 2022, $13M — Ascent Capital

## Investors

- Ascent Capital (https://capitalatlas.ai/funds/ascent-capital) — Series B